TY - JOUR
T1 - Oncolytic virotherapy for pancreatic cancer.
AU - Wennier, Sonia
AU - Li, Shoudong
AU - McFadden, Grant
PY - 2011
Y1 - 2011
N2 - Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.
AB - Within the past decade, many oncolytic viruses (OVs) have been studied as potential treatments for pancreatic cancer and some of these are currently under clinical trials. The applicability of certain OVs, such as adenoviruses, herpesviruses and reoviruses, for the treatment of pancreatic cancer has been intensively studied for several years, whereas the applicability of other more recently investigated OVs, such as poxviruses and parvoviruses, is only starting to be determined. At the same time, studies have identified key characteristics of pancreatic cancer biology that provide a better understanding of the important factors or pathways involved in this disease. This review aims to summarise the different replication-competent OVs proposed as therapeutics for pancreatic cancer. It also focuses on the unique biology of these viruses that makes them exciting candidate virotherapies for pancreatic cancer and discusses how they could be genetically manipulated or combined with other drugs to improve their efficacy based on what is currently known about the molecular biology of pancreatic cancer.
UR - http://www.scopus.com/inward/record.url?scp=80053439755&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80053439755&partnerID=8YFLogxK
U2 - 10.1017/S1462399411001876
DO - 10.1017/S1462399411001876
M3 - Review article
C2 - 21676289
AN - SCOPUS:80053439755
SN - 1462-3994
VL - 13
SP - e18
JO - Expert Reviews in Molecular Medicine
JF - Expert Reviews in Molecular Medicine
ER -